Vertex Pharmaceuticals Incorporated (VX1.DE) Stock Overview
Explore Vertex Pharmaceuticals Incorporated’s financial performance, market position, analyst ratings, and future outlook.
Vertex Pharmaceuticals Incorporated (VX1.DE)
Key Financials
Key Financials
Market Cap
113.3B
P/E Ratio
29.03
EPS (TTM)
$15.68
ROE
0.23%
VX1.DE Stock Analysis & Investment Overview (XETRA)
Our AI-powered analysis of Vertex Pharmaceuticals Incorporated (XETRA: VX1.DE) gives investors deep insight into how the stock performs on the XETRA exchange, its growth potential, and its market positioning. With a Meyka AI Score of B+, Vertex Pharmaceuticals Incorporated's XETRA-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of VX1.DE on the XETRA shows an RSI of 44.41, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $460.04 for the XETRA listing.
Key metrics behind Vertex Pharmaceuticals Incorporated's XETRA-traded stock include a P/E ratio of 29.03 and a market capitalization of 113.3B. Combined with our AI analysis, these give both institutional and retail investors a clear view of VX1.DE on the XETRA.